cas 915087-26-2|| where to buy 4-((1-cyanocyclobutyl)amino)-2-fluoro-N-methylbenzamide

製品名:4-((1-cyanocyclobutyl)amino)-2-fluoro-N-methylbenzamide

IUPAC Name:4-[(1-cyanocyclobutyl)amino]-2-fluoro-N-methylbenzamide

包装単位	有効在庫	価格（USD）
CM201573-10g	in stock	ƀũ
CM201573-25g	in stock	ȺȬƀ
CM201573-100g	in stock	țƦǊ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 915087-26-2 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:915087-26-2; 分子式:C13H14FN3O; 融点:-; SMILESコード:O=C(NC)C1=CC=C(NC2(C#N)CCC2)C=C1F; 密度:

: カタログ番号:CM201573; 分子量:247.27; 沸点:; MDL番号:MFCD09909370; 保管方法:Store at 2-8°C.

: Cyclobutanes; The molecular structure of cyclobutane has four carbon atoms, and its four carbon atoms are not in the same plane, which is the folded conformation of cyclobutane. Cyclobutane itself is not of commercial or biological interest, but more complex derivatives are important in biology and biotechnology. Currently, nine FDA-approved drugs contain the cyclobutane structure. From the perspective of therapeutic areas, cyclobutyl drugs are mainly distributed in popular areas such as tumors, neurological diseases, infectious diseases, endocrine and metabolic diseases.

: Apalutamide; Johnson & Johnson announced results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) and androgen deprivation therapy (ADT) in patients with HRLPC who have undergone radical prostatectomy (RP). Following RP, patients who received the treatment regimen showed a 100% biochemical recurrence (BCR)–free rate at 24 months. ERLEADA® (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.